Professor OjimaIwao Ojima, Distinguished Professor

Director, Institute of Chemical Biology and Drug Discovery
B.S., 1968, The University of Tokyo
M.S., 1970, The University of Tokyo
Ph.D. 1973, The University of Tokyo (Prof. Naoki Inamoto)

Phone: (631) 632-1339
Fax: (631) 632-7942
Email: iwao.ojima@stonybrook.edu
Publications

Appointments:

1973-1983 Senior Research Fellow and Group Leader, Sagami Institute of Chemical Research
1983 Associate Professor, Department of Chemistry, State University of New York at Stony Brook
1984 Professor, Department of Chemistry, State University of New York at Stony Brook
1989 Professeur invité, Université Claude Bernard Lyon I, Lyon, France
1991 Leading Professor, State University of New York at Stony Brook
1995 University Distinguished Professor, State University of New York
1996 Visiting Professor, The University of Tokyo, Tokyo, Japan
1997 Visiting Professor, The Scripps Research Institute, La Jolla, CA
1997 Professeur invité, Université de Paris XI, BIOCIS, Châtenay-Malabry, France
1997-2003 Chairman, Department of Chemistry, State University of New York at Stony Brook
2003-present, Director, Institute of Chemical Biology and Drug Discovery, Stony Brook.

Award and Honors:

The 25th National Young Investigator Award ("Shimpo Sho"), The Chemical Society of Japan, 1976.
Arthur C. Cope Scholar Award, the American Chemical Society, 1994.
The 51st Chemical Society of Japan Award ("Nihon Kagaku Kai Sho") for distinguished achievements, The Chemical Society of Japan, 1999.
Emanuel B. Hershberg Award for Important Discoveries in Medicinally Active Substances, the American Chemical Society, 2001.
Outstanding Inventor Award, The Research Foundation of the State University of New York, 2002.
NYSTAR Faculty Development Award, New York State Office of Science, Technology & Academic Research, 2002.
Inductee, American Chemical Society, Medicinal Chemistry Hall of Fame, 2006.
ACS Award for Creative Work in Fluorine Chemistry, the American Chemical Society, 2013.

Fellow, John Simon Guggenheim Memorial Foundation, 1995.
Fellow, American Association for the Advancement of Science, 1997.
Fellow, New York Academy of Sciences, 2000.
Fellow, American Chemical Society, "ACS Fellow", 2010.

William and Florence Catacosinos Professor in Cancer Research, Stony Brook Foundation, 1994.
Leading Professorship, State University of New York at Stony Brook, 1991
Distinguished Professorship, State University of New York, 1995
He was invited by the Royal Swedish Academy of Sciences to serve as a nominator for the Nobel prize in chemistry for the years 1990, 1996, 2002.
Eli Lilly Lecturer, University of Kansas-Lawrence, 1990.
National Science Council Lecturer, Taiwan, 1990.
J. Clarence Karcher Lecturer, The University of Oklahoma, 1992.
George Lesher Lecturer, Rensselaer Polytechnic Institute, 1995.
Boehringer-Ingelheim Distinguished Lecturer, Colorado State University, 1997.
Weissberger-Williams Lecturer, Eastman Kodak Co., 1997.
Dr. H. Martin Friedman University Lecturer, Rutgers, State University of New Jersey, 2001.
Bristol-Meyers Squibb Distinguished Lecturer, Colorado State University, 2002.
FMC Discovery Chemistry Lecturer, FMC Corporation, 2003.
J. Clarence Karcher Lecturer, The University of Oklahoma, 2003.
Guest Editor, "Drug Resistant Tuberculosis: A Challenge in Chemotherapy", Curr. Topics Med. Chem., 2006.
Guest Editor, "Modern Molecular Approaches to Drug Discovery", Acc. Chem. Res., 2007.
Negishi-Brown Lecturer, Purdue University, 2007.
Guest Editor, "Modern Natural Products Chemistry in Drug Discovery", J. Med. Chem., 2007.
Ralph A. Raphael Lecturer, University of Glasgow, UK, 2008.
The Sosnovsky Distinguished Lectureship, University of Wisconsin Milwaukee, 2008.
Senior Editor, Future Medicinal Chemistry, 2008.
Henry J. Shine Lecturer, Texas Tech University, 2009.
National Science Council Lecturer, Taiwan, 2011.
The Ohdang Lectureship Award, The Pharmaceutical Society of Korea, Korea, 2012.
Distinguished Lectureship in Medicinal Chemistry, University of Minnesota, 2013

Professional Activities:

(Senior Editor)
Future Medicinal Chemistry (2008-)
(Advisory Board)
1. Editorial Advisory Board of Journal of Molecular Catalysis (1986-1995)
2. Editorial Advisory Board of Journal of Organic Chemistry (ACS) (1995-1999)
3. Editorial Advisory Board of Organometallics (ACS) (1996-1998)
4. Editorial Advisory Board of Current Topics in Medicinal Chemistry (2002-)
5. Editorial Advisory Board of Letters in Drug Design & Discovery (2003-)
6. Editorial Advisory Board of Medicinal Chemistry (2004-)
7. Editorial Advisory Board of Bull. Chem. Soc. Jpn (2005-)
8. Editorial Advisory Board of Anti-Cancer Agents in Medicinal Chemistry (2006-)
9. Basic Science Advisory Board member, Stony Brook University Cancer Center (1999-).
10. Stony Brook University Research Park Oversight Board (2007-).
11. Cell in Motion – CiM, Cluster of Excellence, University of Muenster, Germany (2012-).
(Symposia and Conferences)
1. Chairperson, The Stony Brook Symposium on Taxol and Taxotère, "New Hope for Breast Cancer Chemotherapy" Stony Brook, NY, May (1993).
2. Chairperson, Symposium on "Recent Advances in the Chemistry of Taxane and Taxoid Anticancer Agents", 207th American Chemical Society National Meeting, San Diego, CA, March (1994).
3. Chairperson, Symposium on "Fluoroamino Acids and Peptides in Medicinal Chemistry", 210th American Chemical Society National Meeting, Chicago, IL, August (1995).
4. Organizer and Chairperson, Symposium on "New Prospects in Anticancer Agents for the 21st Century" 219th American Chemical Society National Meeting, San Francisco, CA, March (2000).
5. Organizer, Ernest Guenther Award Symposium", the 219th American Chemical Society National Meeting, San Francisco, CA, March 2000.
6. Organizer, Ernest Guenther Award Symposium, the 229th American Chemical Society National Meeting, San Diego, CA, March (2005).
7. Organizer, Symposium on "Drug Resistant Tuberculosis – Challenge in Chemotherapy", the 229th American Chemical Society National Meeting, San Diego, CA, March (2005).
8. Organizer, ACS Award in Organometallic Chemistry Symposium, the 231st American Chemical Society National Meeting, Atlanta, GA, March (2006).
9. Organizer, "Modern Natural Products Chemistry and Drug Discovery" Symposium, the 231st American Chemical Society National Meeting, Atlanta, GA, March (2006).
10. Organizer, "Ernest Guenther Award Symposium, the 233rd American Chemical Society National Meeting, Chicago, IL, March (2007).
11. Organizer, "Modern Molecular Strategies for Tumor-Targeting Drug Dilivery", the 234th American Chemical Society National Meeting, Boston, MA, August (2007)
(Advisory Committee, Panel Reviewer)
1. Advisory Committee Member, NIH, Medicinal Chemistry (MCHA) Study Section (1988-1992).
2. Ad Hoc Member, Triennial Oversight Committee, Chemistry Division, NSF (1992).
3. Panel Reviewer, Basic Energy Science Program, U. S. Department of Energy (1992).
4. Advisory Committee Member Reserve, NIH (1992-1995).
5. Panel Reviewer, REU Program, Chemistry Division, NSF (1992).
6. Panel Reviewer, NSF Postdoctoral Fellowship in Chemistry (1994).
7. Chemistry and Related Sciences Special Emphasis Panel, NIH, Bioorganic and Natural Product Chemistry (BNP-1) Program (1995).
8. Special Panel Reviewer, NIH, Medicinal Chemistry (MCHA) Study Section (1995).
9. Chemistry and Related Sciences Special Emphasis Panel, NIH, Bioorganic and Natural Product Chemistry (BNP-1) Program (1996).
10. Chemistry and Related Sciences Special Emphasis Panel, NIH, SBIR and STTR Programs (1996).
11. Panel Reviewer, NSF Small Business Innovation Research (SBIR) Program (1997).
12. Special Panel Reviewer, NIH, Medicinal Chemistry (MCHA) Study Section (1998).
13. Special Panel Reviewer, NIH, Medicinal Chemistry (MCHA) Study Section (2001).
14. Special Panel Reviewer, NIH, Bioorganic and Natural Product Chemistry (BNP) Study Section (2002).
15. Panel Reviewer, NCI, Basic & Preclinical Subcommittee IRG (2002).
16. Panel Reviewer, NCI, Basic & Preclinical Subcommittee IRG (2003).
17. Panel Reviewer, NIH, Drug Discovery & Molecular Pharmacology (DMP) Study Section, Oncological Sciences IRG (2004).
18. Panel Reviewer, NCI, National Cooperative Drug Discovery Groups for Cancer (NCDDG) IRG (2004).
19. Special Emphasis Panel Reviewer, NCI, ONC-K Study Section (2005).
20. Special Emphasis Panel Reviewer, NIH, BCMB-B Study Section (2005).
21. Special Emphasis Panel Reviewer, NIH, BCMB-B Study Section (AIR, AED) (Feb. and July 2008)
22. Panel Reviewer, NIH, Synthetic and Biological Chemistry A (SBCA) Study Section (June 2009)
23. Special Emphasis Panel Reviewer, NIH Challenge Grant (June 2009)
24. Panel Reviewer, NIH, SBIR/STTR Cancer Drug Development Study Section (July 2009)
25. Special Emphasis Panel Reviewer, NIH, BCMB-B Study Section (September 2010)
26. Special Emphasis Panel Reviewer, NIH, NIAID Biodefense Study Section (October 2011)
27. Panel Reviewer, NCI, SBIR Contract, Development of Anticancer Agents Study Section (March 2012)
28. Special Emphasis Panel Reviewer, NIH, NIAID Biodefense Study Section (September 2012)
29. Special Emphasis Panel Reviewer, NIH, NCI, SBIR Bridge Award Study Section (June 2013)
30. Special Emphasis Panel Reviewer, NIH, NIAID, CETR Study Section (July/September 2013)

(American Chemical Society)
1. Executive Committee Member, Division of Organic Chemistry, American Chemical Society (1998-2001).
2. Long Range Planning Committee, Division of Medicinal Chemistry, American Chemical Society (2003-2006).

Consulting:

He has served as a consultant for E. I. du Pont, Eli Lilly, Air Products & Chemicals, Mitsubishi Chem. Corp, Nippon Steel Corp. Life Science Division, Rhone-Poulenc Rorer, ImmunoGen, Inc., Taiho Pharmaceutical Co., Milliken & Co., Aventis Pharma, OSI Pharmaceuticals, Inc., INDENA, SpA, Central Glass Co., Ajinomoto Co., Inc. (current), ChemMaster International (current), Tayler Wessing LLP (current), Fujian Yew Park Biological Co., Ltd. (current).

Memberships

He is a member of American Chemical Society, American Association for the Advancement of Science, American Association for Cancer Research, American Peptide Society, New York Academy of Sciences, Sigma Xi, The Chemical Society of Japan, and The Society of Synthetic Organic Chemistry, Japan.

Research Interest and Activities:

His research interests include drug design and discovery (anticancer agents, antibacterial agents, enzyme inhibitors), medicinal chemistry and chemical biology, catalytic asymmetric synthesis, organic synthesis by means of organometallic reagents and catalysts, homogeneous catalysis and organometallic chemistry, peptide and peptidomimetics, -lactam chemistry, and organofluorine chemistry (fluoroamino acids and peptides, fluorotaxoids, medicinal applications). He has published more than 400 papers and reviews in leading journals and more than l00 patents granted, edited 8 books, and he has given more than 120 Plenary and Invited Lectures in international conferences and symposia by November 2013. SciFinder lists more than 850 publications to his credit. Google Scholar indicates 17,274 citations, h-index 61 and i10-index 272 as of November 2013. He has also given numerous invited lectures at universities, research institutes, and industries (total >480 since his move to Stony Brook in 1983).

Selected Plenary and Invited Lectures in International Meetings since 2008:

95. First International Conference on Drug Design and Discovery, Dubai, UAE, February 3-6, 2008. "Design, Application, and Chemical Biology of Tumor-Targeting Drug Conjugates".
96. The Ernest Guenther Award Symposium, 235th American Chemical Society National Meeting, New Orleans, LA, April 6-9, 2008. "Taxane-based Tumor-targeting Anticancer Agents".
97. The Award Symposium on Fluorine Chemistry, 235th American Chemical Society National Meeting, New Orleans, LA, April 6-9, 2008. "Medicinal Chemistry and Chemical Biology of Fluoro-taxoids Anticancer Agents".
98. Swiss Chemical Society, Medicinal Chemistry Division Mini-Symposium on Drug Targeting, Basel, Switzerland, May 29, 2008. "Design, Application, and Chemical Biology of Tumor-Targeting Drug Conjugates".
99. 6th University of Glasgow – Schering-Plough Symposium on Synthetic Chemistry, Glasgow, UK, August 28, 2008. "Synthetic Organic Chemistry at the Biomedical Interface".
100. 6th University of Glasgow – Schering-Plough Symposium on Synthetic Chemistry, Glasgow, UK, August 29, 2008. "Rapid Construction of Fused Heterocycles and Carbocycles by Catalytic Cyclizations and Cycloadditions".
101. 2nd World Congress on Magic Bullets, Nürnberg, Germany, October 3-5, 2008. "Taxane-Based Tumor-Targeting Anticancer Agents".
102. International Symposium on Fluorine-Containing Peptides, Tokyo, Japan, November 4, 2008. "Synthesis of Fluorinated Amino Acids, Dipeptides, and Taxoids by Means of -Lactam Synthon Method".
103. 19th American Chemical Society Winter Fluorine Conference, St. Petersburg, FL, January 11-16, 2009. "Medicinal chemistry and chemical biology of fluorine-containing taxoid anticancer agents".
104. 19th International Symposium on Fluorine Chemistry, Jackson Hole, WY, August 23-28, 2009, "Synthesis of Fluorinated -Hydroxy--amino Acids by Means of -Lactam Synthon Method and Their Applications to Medicinal Chemistry".
105. 1st Tishler-Omura Symposium, Tokyo, Japan, October 30, 2009. "Synthetic Organic Chemistry at the Biomedical Interface".
106. 3rd International Symposium on Nanomedicine (ISNM-2009), Okazaki, Japan, November 4-6, 2009. "Functionalized SWNTs as Vehicles for Tumor-Targeting Drug Delivery".
107. Perugia Fluorine Days: Organofluorine Compounds in Biomedical and Agricultural Sciences, Perugia, Italy, July 11-15, 2010. "Medicinal Chemistry and Chemical Biology of Fluorine-Containing Taxoid Anticancer Agents".
108. 11th Eurasia Conference on Chemical Sciences (EuAsC2S-11), The Dead-Sea, Jordan, October 6-10, 2010. "Tumor-Targeting Drug Delivery of Chemotherapeutic Agents".
109. 10th Tateshina Conference on Organic Chemistry, Tateshina, Japan, Novermber 12-14, 2010. "Chemistry and Chemical Biology of Tumor-Targeting Anticancer Agents".
110. 2nd Word Congress on Catalytic Asymmetric Synthesis (WCCAS-2011), Beijing, China, August 9-11, 2011. "Catalytic Asymmetric Synthesis with Novel Biphenol-Based Chiral Ligands".
111. 2nd International Conference of Medichem (ICM-2011), Beijing, China, August 9-11, 2011. 'Design and Development of "Guided Molecular Missiles" for Tumor-Targeting Chemotherapy".
112. 12th Conférence Universitaire de Suisssse Occidentale (CUSO) Summer School, Villars, Switzerland, August 28 – September 1, 2011. "Synthetic Organic Chemistry at the Biomedical Interface".
113. 12th Conférence Universitaire de Suisssse Occidentale (CUSO) Summer School, Villars, Switzerland, August 28 – September 1, 2011. "New Strategy for the Rapid Construction of Fused Ring Systems of Biological Interest".
114. 12th Conférence Universitaire de Suisssse Occidentale (CUSO) Summer School, Villars, Switzerland, August 28 – September 1, 2011. "Catalytic Asymmetric Synthesis with Novel Biphenol-Based Phosphorus Ligands".
115. International Research Training Group (IRTG) Mini-Symposium, Münster, Germany, November 11, 2011. "Synthetic Organic Chemistry at the Biomedical Interface".
116. 3rd International Symposium on Organofluorine Compounds in Biomedical, Materials and Agricultural Sciences, Valencia, Spain, May20-24, 2012. "Fluorine-Containing Taxoid Anticancer Agents and Their Tumor-Targeted Drug Delivery".
117. International Convention of The Pharmaceutical Society of Korea, Seoul, Korea, October 23-24, 2012. "Tumor-Targeting Drug Delivery of Chemotherapeutic Agents".
118. International Drug Discovery Science and Technology Conference, Nanjing, China, November 8-10, 2012. "Targeting Prostate, Colon and Breast Cancer Stem Cells with New Generation Taxoids".
119. International Symposium of Drug Delivery Systems, Nanjing, China, November 8-10, 2012. "Tumor-Targeting Drug Conjugates of New Generation Taxoids".
120. 21st Winter Fluorine Conference, American Chemical Society, St. Petersburg, FL, January 13-18, 2013. "Exploration of Fluorine Chemistry at the Biomedical Interface in Perspective - A Personal Account".
121. 245th American Chemical Society National Meeting, New Orleans, LA, April 9-12, 2013. "Exploration of Fluorine Chemistry at the Biomedical Interface".
122. International Fluorine Workshop, Tokyo, Japan, April 13-14, 2013. "Exploration of Fluorine Chemistry at the Biomedical Interface in Perspective".
123. Congress of International Drug Discovery Science & Technology, Therapy and EXPO, Haikou, China, November 13-16, 2013. "New Generation Antibacterial Drug Discovery Targeting Bacterial Cell Division".
124. Congress of International Drug Discovery Science & Technology, Therapy and EXPO, Haikou, China, November 13-16, 2013. "New Generation Taxoid Anticancer Agents and Their Tumor-Targeted Drug Delivery".

Invited Lectures Since 2008:

427 City University of New York, Hunter College, NYC, NY [March 28, 2008, W. Herding]
428 Swiss Federal Institute of Technology, Lausanne (EPFL), Institute of Chemical Sciences and Egineering, Lausanne, Switzerland [May 27, 2008, K. Gademann]
429 F. Hoffmann-La Roche, AG, Pharma Research, Basel, Switzerland [May 30, 2008, H. P. Maerki, T. Woltering]
430 Université Pierre et Marie Curie (Paris VI), Institut de Chimie Moléculaire, Paris, France [June 2, 2008, L. Fensterbank, M. Maracria]
431 Université de Cergy-Pontoise, Laboratoire "Synthèse Organique Sélective et Chimie Organométallique", Cergy-Pontoise, France [June 3, 2008, T. Brigaurd]
432 Sanofi-Aventis, Chemical and Analytical Sciences, Vitry-sur-Seine, France [June 5, 2008, A. Commerçon]
433 Sundia Pharamceuticals, Inc., Shanghai, China [June 24, 2008, J. Zhu]
434 University of Wisconsin Milwaukee, Milwaukee, WI [Oct. 16-17, 2008, J. Cook] (Inaugural Sosnovsky Lectures; two lectures)
435 Central Glass Co., Chemical Research Center, Kawagoe, Japan [Oct. 27, 2008, N. Takada, Y. Hibino]
436 RIKEN (The Institute of Physical and Chemical Research), Wako, Saitama, Japan [Oct. 28, 2008, M. Sodeoka]
437 The University of Tokyo, School of Engineering, Hongo, Tokyo, Japan [Oct. 29, 2008, M. Fujita]
438 Mitsubishi Chemical Group, Science and Technology Center, Yokohama, Japan [Oct. 30, 2008, M. Takai]
439 Ajinomoto Co., Inc., Pharmaceutical Research Institute, Kawasaki, Japan [Nov. 5, 2008, M. Shoji]
440 Kitasato Institute, Shirogane, Tokyo, Japan [Nov. 14, 2008, S. Omura]
441 Texas Tech University, Lubbock, TX [Feb. 24-25, 2009, G. Lee]
442 Genentech, South San Francisco, CA [April 8, 2009, F. Cohen]
443 National Cancer Institute-Frederic, Frederic-SAIC, Inc., Bethesda, MD [May 27, 2009, S. Malhotra, A. Pepe]
444 Nagoya Institute of Technology, Nagoya, Japan [Nov. 10, 2009, N. Shibata]
445 Ajinomoto Co., Inc., Pharmaceutical Research Institute, Kawasaki, Japan [Nov. 11, 2009, E. Nakanishi]
446 Chugai Pharmaceuticals Kamakura Research Center, Kamakura, Japan [Nov. 12, 2009, N. Shimma]
447 The University of Tokyo, Graduate School of Chemistry, Hongo, Tokyo, Japan [Nov. 14, 2009, E. Nakamura]
448 The Tosoh Organic Synthesis Seminar, Odaiba, Tokyo, Japan [April 22, 2010, K. Kato]
449 Ajinomoto Pharmaceuticala Co. Ltd., Pharmaceutical Research Laboratory, Kawasaki, Japan [Nov. 4, 2010, K. Sakurai, T. Tsuji]
450 Kitasato Institute and Kitasato University, Sirogane, Tokyo, Japan [Nov. 5, 2010, T. Sunazuka, S. Omura]
451 Shonan High School, Fujisawa, Japan [Nov. 6, 2010, M. Kato, A. Komuro]
452 Central Glass KK, Chemical Research Center, Kawagoe, Japan [Nov. 8, 2010, Y. Hibino]
453 The University of Tokyo, Graduate School of Pharmaceutical Science, Hongo, Tokyo, Japan [Nov. 9, 2010, T. Fukuyama]
454 Johns Hopkins School of Medicine, Department of Pharmacology and Molecular Sciences, Baltimore, MD [March 2, 2011, J. Liu]
455 Colorado State University, Department of Microbiology, Immunology and Pathology, Fort Collins, CO [June 27, 2011, R A. Slayden]
456 National Chiao-Tung University, Department of Chemistry, Hsin-Chu, Taiwan [August 1, 2011, C.-M. Sun]
457 National Health Research Institutes, Zhu-Nan, Taiwan [August 2, 2011, H.-P. Hsieh]
458 National Chung Cheng University, Department of Chemistry and Biochemistry, Chia-Yi, Taiwan [August 3, H.-J. Chen]
459 National Taiwan University, Department of Chemistry, Taipei, Taiwan [August 5, T-Y. Luh]
460 Pharmaron Beijing, Beijing, China [August 8, 2011, B. Lou, H. Yang, J. Wei]
461 Swiss Federal Institute of Technology (ETH), Institute of Pharmaceutical Sciences, Zurich, Switzerland [September 2, 2011, K.-H. Altmann]
462 Sanofi-Aventis, Division of Infectious Diseases, Toulouse, France [September 6, 2011, L. Fraisse, G. Courtemanche]
463 The University of Tokyo, Graduate School of Engineering, Tokyo, Japan [October 24, 2011, M. Fujita]
464 Keio University, Department of Chemistry, Yokohama, Japan [October 26, 2011, T. Yamada]
465 Central Glass Co. Ltd., Chemical Research Center, Saitama, Japan [October 27, 2011, T. Kume, Y. Hibino]
466 Ajinomoto Pharmaceuticals, Co., Ltd., Pharmaceutical Research Center, Kawasaki, Japan [October 31, T. Tsuji, K. Sakurai]
467 Hamari Chemicals Ltd., Osaka, Japan [November 7, 2011, T. Takami, H. Moriwaki]
468 Kitasato Institute and University, Tokyo, Japan [January 18, 2012, T. Sunazuka]
469 RIKEN, Advanced Science Institute, Saitama, Japan [January 19, 2012, Z. Hou]
470 Kanagawa University, Faculty of Science, Department of Chemistry, Kanagawa, Japan [January 20, 2012, M. Matsumoto]
471 University of Barcelona, Institute of Organic Chemistry, Barcelona, Spain [May 25, 2012, J. Garcia Gomez]
472 University of Ikebasque, Department of Chemistry, San Sebastian, Spain [May 29, 2012, V. Soloshonok]
473 Centro de Investigaciones Biologicas (CIB), National Research Council (CSIC), Mardrid, Spain [June 1, 2012. J. F. Diaz Pereira]
474 Department of Chemistry, Xiamen University, Xiamen, China [June 21, 2012, Y. Zhao]
475 Haikou Municipal Hospital and Central South University School of Medicine, Haikou, Hainan, China [June 23, 2012, G. Tian]
476 Chungnam National University, College of Pharmacy, Daejon, Korea [October 24, 2012, S.-H.Jung]
477 The University of Tokyo, Department of Applied Chemistry, Tokyo, Japan [October 30, 2012, M. Fujita]
478 Ajinomoto Pharmaceuticals Co. Ltd., Pharmaceutical Research Center, Kawasaki, Japan [October 31, 2012, T. Tsuji, K. Sakurai]
479 Central Glass Co. Ltd., Chemical Research Center, Kawagoe, Japan [November 1, 2012, Y. Ishi, M. Fujiwara]
480 Shanghai Institute of Materia Medica, Shanghai, China [November 16, 2012, H. Liu]
481 University of Minnesota, Department of Medicinal Chemistry, Minneapolis, MN [September 17, 2013, C. Haskell-Luevano]
482 Rutgers, State University of New Jersey, College of Pharmacy, New Brunswick, NJ [September 24, 2013, E. Lavoie]
483 The University of Tokyo, Graduate School of Chemistry, Tokyo, Japan [November 5, 2013, E. Nakamura]
484 Ajinomoto Pharmaceuticals Co. Ltd., Pharmaceutical Research Center, Kawasaki, Japan [November 7, 2013, K. Sakurai]
485 Central Glass Co. Ltd., Chemical Research Center, Kawagoe, Japan [November 8, 2013, T. Komata]
486 Guangzhou Institutes of Biomedicine and Health, Drug Discovery Pipeline, Guangzhou, China [November 18, 2013, M. Tortorella]
487 Guangzhou Institutes of Biomedicine and Health, Guangzhou, China [November 19, 2013, Ding Ke, M. Tortorella]
488 Sundia MediTech, Shanghai, China [November 21, 2013, J. Zhu]

In addition to these invited lectures, he and his laboratory members regularly present papers at the American Chemical Society's National Meetings, ACS Winter Fluorine Conference, American Association for Cancer Research (AACR) Annual Meeting.

Back to top

Professor Ojima
Department of Chemistry, Stony Brook University, Stony Brook, New York 11794-3400 Phone: (631) 632-7890
Login to Edit